Edition:
United States

Advanced Search

Display
per page
  Report Title Date Provider Type Pgs Price

Aldeyra Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

24 Sep 2016 Reuters Investment Profile 12 $20.00

ValuEngine Rating and Forecast Report for ALDX

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

25 Sep 2016 ValuEngine, Inc. 11 $25.00

ALDEXA THERAPEUTICS INC (ALDX=US) - SHORT AND LONG TERM FORECASTS FOR ACTIVE TRADERS

"www.pechala.com, the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

24 Sep 2016 Pechala's Reports 2 $25.00

Laidlaw: ALDX: 2Q16: Six clinical programs to start in late 2016 and 2017 including first systemic NS2 in rare diseases

This morning, ALDX reported 2Q16 financial results with a net loss of ($4.3MM) and net loss per share of ($0.41). ALDX ended ...

10 Aug 2016 Laidlaw & Company 8 $25.00

Laidlaw: ALDX: Robust NS2 in Sjӧgren-Larsson Syndrome (SLS) Phase II results

This morning, ALDX reported positive NS2 in SLS (n=12) Phase II results which met primary endpoint of Ichthyosis Severity Sco...

09 Aug 2016 Laidlaw & Company 9 $25.00

Laidlaw: ALDX: 1Q16: Positive POC top-line results of NS2 in noninfectious anterior uveitis Phase II trial

This morning, ALDX reported 1Q16 financial results with a net loss of ($5.0MM) and net loss per share of ($0.51). ALDX ended ...

09 May 2016 Laidlaw & Company 8 $25.00

ALDX: 4Q15: Top-line results of NS2 in two Phase II trials expected in 2Q/3Q16 are near-term catalysts

This morning, ALDX reported 4Q15 financial results with a net loss of ($4.3MM), net loss per share of ($0.44) and cash of $27...

30 Mar 2016 Laidlaw & Company 7 $25.00

ALDX.OQ - Event Transcript of Aldeyra Therapeutics Inc conference call, Mar. 30, 2016 / 8:30AM ET

Edited Event Transcript of ALDX.OQ conference call, Mar. 30, 2016 / 8:30AM ET Boston, Mar 31, 2016 (Thomson StreetEvent...

30 Mar 2016 Thomson Reuters StreetEvents 9 $75.00

ALDX: Positive NS2 in allergic conjunctivitis Phase IIa trial results would be a major clinical validation for aldehyde trapping

This morning, ALDX reported positive NS2 in allergic conjunctivitis (AC) Phase IIa trial results. The drug achieved statist...

29 Feb 2016 Laidlaw & Company 8 $25.00

Thomson Reuters Stock Report - Aldeyra Therapeutics Inc (ALDX-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

29 Feb 2016 Thomson Reuters Stock Report 12 $25.00